Telomir Pharmaceuticals reported significant progress in addressing age-related macular degeneration (AMD) through its experimental oral therapeutic, Telomir-1. In a 14-day preclinical study using a genetically modified zebrafish model, the drug demonstrated remarkable potential for vision restoration and retinal regeneration.
The study revealed multiple promising outcomes, including improved central vision response, comprehensive retinal architecture restoration, and a substantial 50% reduction in oxidative stress. Notably, the treatment eliminated mortality observed in untreated animals and facilitated complete visual function recovery.
Researchers observed structural regeneration across critical retinal layers, specifically in the inner nuclear and ganglion cell layers. These findings suggest Telomir-1 could represent a groundbreaking approach to treating degenerative eye conditions associated with aging.
The research aligns with Telomir's broader scientific mission of developing interventions that target fundamental aging processes. By focusing on telomere preservation—the protective DNA chromosome caps that naturally shorten with age—the company aims to develop treatments that could potentially mitigate age-related diseases.
While preclinical results are promising, further research and human trials will be necessary to validate the therapeutic potential of Telomir-1 for vision restoration and potential broader applications in longevity science.
